Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

A Braat; Dik Kwekkeboom; BLR Kam; Jaap Teunissen; W.W. de Herder; KMA Dreijerink; R Rooij; GC Krijger; H Jong; M Bosch; MGEH Lam

doi:10.1186/s12876-018-0817-8

Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

A Braat, Dik Kwekkeboom, BLR Kam, Jaap Teunissen, W.W. de Herder, KMA Dreijerink, R Rooij, GC Krijger, H Jong, M Bosch, MGEH Lam

Research output: Contribution to journal › Article › Academic

31 Citations (Scopus)

12 Downloads (Pure)

Original language	Undefined/Unknown
Article number	84
Journal	BMC Gastroenterology
Volume	18
DOIs	https://doi.org/10.1186/s12876-018-0817-8
Publication status	Published - 2018

Research programs

EMC MM-01-39-01
EMC NIHES-03-30-01

Access to Document

10.1186/s12876-018-0817-8

REPUB_108888-OA.pdfFinal published version, 1.24 MB

http://hdl.handle.net/1765/108888

Cite this

Braat, A., Kwekkeboom, D., Kam, BLR., Teunissen, J., de Herder, W. W., Dreijerink, KMA., Rooij, R., Krijger, GC., Jong, H., Bosch, M., & Lam, MGEH. (2018). Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterology, 18, Article 84. https://doi.org/10.1186/s12876-018-0817-8

@article{730a6e47299e41aa8ad774c2b1257c4f,

title = "Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)",

author = "A Braat and Dik Kwekkeboom and BLR Kam and Jaap Teunissen and {de Herder}, W.W. and KMA Dreijerink and R Rooij and GC Krijger and H Jong and M Bosch and MGEH Lam",

year = "2018",

doi = "10.1186/s12876-018-0817-8",

language = "Undefined/Unknown",

volume = "18",

journal = "BMC Gastroenterology",

issn = "1471-230X",

publisher = "BioMed Central Ltd.",

}

Braat, A, Kwekkeboom, D, Kam, BLR, Teunissen, J, de Herder, WW, Dreijerink, KMA, Rooij, R, Krijger, GC, Jong, H, Bosch, M & Lam, MGEH 2018, 'Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)', BMC Gastroenterology, vol. 18, 84. https://doi.org/10.1186/s12876-018-0817-8

Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). / Braat, A; Kwekkeboom, Dik; Kam, BLR et al.
In: BMC Gastroenterology, Vol. 18, 84, 2018.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

AU - Braat, A

AU - Kwekkeboom, Dik

AU - Kam, BLR

AU - Teunissen, Jaap

AU - de Herder, W.W.

AU - Dreijerink, KMA

AU - Rooij, R

AU - Krijger, GC

AU - Jong, H

AU - Bosch, M

AU - Lam, MGEH

PY - 2018

Y1 - 2018

U2 - 10.1186/s12876-018-0817-8

DO - 10.1186/s12876-018-0817-8

M3 - Article

C2 - 29902988

SN - 1471-230X

VL - 18

JO - BMC Gastroenterology

JF - BMC Gastroenterology

M1 - 84

ER -

Braat A, Kwekkeboom D, Kam BLR, Teunissen J, de Herder WW, Dreijerink KMA et al. Additional hepatic Ho-166-radioembolization in patients with neuroendocrine tumours treated with Lu-177-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterology. 2018;18:84. doi: 10.1186/s12876-018-0817-8